Dow obtains new oligonucleotides contact

- Last updated on GMT

Related tags: Oligonucleotide

Dow Chemical has agreed for Dowpharma, Dow's pharmaceutical
manufacturing services business unit, to supply select, proprietary
oligonucleotides to Montreal, Canada-based Topigen Pharmaceuticals
for use in its pharmaceutical development programme.

Dow Chemical has agreed for Dowpharma, Dow's pharmaceutical manufacturing services business unit, to supply select, proprietary oligonucleotides to Montreal, Canada-based Topigen Pharmaceuticals for use in its pharmaceutical development programme.

Topigen's pharmaceutical development programme - based primarily on a synergistic blend of antisense oligonucleotides - is directed toward the treatment of a range of inflammatory respiratory diseases and is predicated on engaging multiple genes.

Dowpharma will supply the Canadian firm with oligonucleotides as its antisense-based products move through the phases of clinical trials to commercial production. Dowpharma is currently providing clients with both laboratory, and mid-scale, cGMP oligonucleotide development and manufacturing capabilities. A commercial unit, with an annual capacity of around 500kg, will be on-line later in 2003, the company said.

Related news

Show more

Related products

show more

Facilities: Lexington, KY USA

Facilities: Lexington, KY USA

Piramal Pharma Solutions | 23-Aug-2021 | Insight Guide

The Piramal Pharma Solutions facility in Lexington, KY USA is a fully integrated site which offers analytical, formulation development, and manufacturing...

Facilities: Sellersville, PA USA

Facilities: Sellersville, PA USA

Piramal Pharma Solutions | 23-Aug-2021 | Insight Guide

The Piramal Pharma Solutions facility in Sellersville, PA USA is a fully integrated site that offers product and process development, clinical supply and...

Related suppliers

Follow us

Products

View more

Webinars